Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial

BACKGROUND: Extending the duration of adjuvant endocrine therapy reduces the risk of recurrence in a subset of women with early-stage hormone receptor-positive (HR+) breast cancer. Validated predictive biomarkers of endocrine response could significantly improve patient selection for extended therap...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Bartlett, J M S, Sgroi, D C, Treuner, K, Zhang, Y, Ahmed, I, Piper, T, Salunga, R, Brachtel, E F, Pirrie, S J, Schnabel, C A, Rea, D W
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6927322/
https://ncbi.nlm.nih.gov/pubmed/31504126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz289
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados